1
|
Haddad SA, Spring LM, Jimenez RB, Vidula N, Comander A, Shin JA, Coopey SB, Gadd MA, Hughes KS, Taghian A, Smith BL, Isakoff SJ, Moy B, Bardia A, Specht MC. Abstract P2-14-19: Surgical and long-term outcomes of patients receiving neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-14-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The addition of pertuzumab to trastuzumab and chemotherapy significantly improves the pathologic complete response (pCR) rate in HER2+ localized breast cancer in the preoperative setting. Although many patients are converted to breast conserving therapy (BCT) candidates by neoadjuvant HER2-directed therapy, a significant proportion opt for a mastectomy for various reasons. Among mastectomy procedures, nipple sparing mastectomy (NSM) is frequently chosen instead of non-nipple sparing mastectomy (NNSM). In this study, we evaluated the surgical and long-term outcomes of HER2+ patients receiving neoadjuvant pertuzumab-containing regimens.
Methods: We performed a retrospective review of localized breast cancer patients treated with neoadjuvant pertuzumab-containing regimens from 2011 to 2016, who underwent BCT or mastectomy at an academic institution and two community-based practices. Disease characteristics, treatment regimens, surgical outcomes, and recurrence data were extracted from the electronic medical records.
Results: Among 90 patients with stage II-III HER2+ breast cancer, 45 received AC-THP (50.0%), 26 received THP (with adjuvant AC) (29.0%), and 19 received TCHP (21.0%). The majority of patients had grade 3 tumors (61.1%), clinical stage II disease (80.0%), invasive ductal carcinoma (86.7%), and ER+ disease (65.6%). Thirty-seven (41.0%) patients underwent BCT and 53 (59.0%) patients underwent mastectomy. Among the mastectomy patients, 38 (71.7%) patients underwent bilateral mastectomies, specifically 33 (62.0%) patients underwent a NSM and 20 (38.0%) patients underwent a NNSM. The type of surgery that patients underwent stratified by type of neoadjuvant regimen is outlined in the Table 1 below. Most patients who underwent BCT and mastectomy received radiation, including 36 (97.3%) BCT, 24 (72.7%) NSM, and 18 (95.0%) NNSM. Over a median follow-up period of 33 months, 6 patients (6.7%) had recurrences with 2 (2.2%) local recurrences and 4 (4.4%) distant recurrences. The 2 local recurrences occurred in one patient who underwent BCT and one patient who underwent NNSM followed by post-mastectomy radiation.
Conclusions: Among mastectomy patients, NSM was more commonly pursued than NNSM. Rates of local recurrence following pertuzumab-containing regimens for HER2-positive localized breast cancer were low overall, regardless of the type of surgery. Data on plastic surgery approaches and complication rates will be presented at the meeting.
Table 1.Type of surgery in patients receiving neoadjuvant HER2-directed therapy. AC-THP (N = 45)TCHP (N = 19)THP (N = 26)BCT46.7%47.4%26.9%NNSM26.7%10.5%23.1%NSM26.7%42.1%50.0%
Citation Format: Haddad SA, Spring LM, Jimenez RB, Vidula N, Comander A, Shin JA, Coopey SB, Gadd MA, Hughes KS, Taghian A, Smith BL, Isakoff SJ, Moy B, Bardia A, Specht MC. Surgical and long-term outcomes of patients receiving neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-14-19.
Collapse
Affiliation(s)
- SA Haddad
- Massachusetts General Hospital, Boston, MA
| | - LM Spring
- Massachusetts General Hospital, Boston, MA
| | - RB Jimenez
- Massachusetts General Hospital, Boston, MA
| | - N Vidula
- Massachusetts General Hospital, Boston, MA
| | - A Comander
- Massachusetts General Hospital, Boston, MA
| | - JA Shin
- Massachusetts General Hospital, Boston, MA
| | - SB Coopey
- Massachusetts General Hospital, Boston, MA
| | - MA Gadd
- Massachusetts General Hospital, Boston, MA
| | - KS Hughes
- Massachusetts General Hospital, Boston, MA
| | - A Taghian
- Massachusetts General Hospital, Boston, MA
| | - BL Smith
- Massachusetts General Hospital, Boston, MA
| | - SJ Isakoff
- Massachusetts General Hospital, Boston, MA
| | - B Moy
- Massachusetts General Hospital, Boston, MA
| | - A Bardia
- Massachusetts General Hospital, Boston, MA
| | - MC Specht
- Massachusetts General Hospital, Boston, MA
| |
Collapse
|
2
|
Nakhlis F, Harrison BT, Lester SC, Hughes KS, Coopey SB, King TA. Abstract P5-22-01: Evaluating the risk of upgrade to invasive breast cancer and/or DCIS on excision following a diagnosis of non-classic lobular carcinoma in situ. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-22-01] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Non-classic lobular carcinoma in situ (NC-LCIS) is a rare pathologic entity which encompasses a variety of histologic diagnoses. As such its natural history, including upgrade rates to invasive cancer (IC) or ductal carcinoma in situ (DCIS) on excision, is poorly characterized. We sought to evaluate the risk of upgrade to IC or DCIS when NC-LCIS is diagnosed on core biopsy.
Methods: After obtaining IRB approval, institutional pathology databases were searched for NC-LCIS core biopsy diagnoses (carcinoma in situ (CIS), carcinoma in situ with ductal and lobular features (CIS/DLF), pleomorphic LCIS (P-LCIS), variant LCIS (V-LCIS), LCIS with necrosis). Cases with a NC-LCIS core biopsy diagnosis and with available pathology results from subsequent surgery were included. Cases with known concurrent ipsilateral IC, DCIS and/or atypical ductal hyperplasia were excluded.
Results: 107 cases with NC-LCIS in any pathology report were identified (1998-2016); 44 were excluded due to concurrent ipsilateral IC, the remaining 62 patients with 63 core biopsy diagnoses of NC-LCIS all underwent surgical excision and formed our study cohort. Median age was 56 years (range 43-83); 43 (68%) were postmenopausal. NC-LCIS was diagnosed on core biopsy for mammographic findings in 57 (90%) cases and for MRI findings in 6 (9%). All were BI-RADS 4 lesions; calcifications were the most common biopsy indication (50 (78%)). CIS/DLF was the most common term used for NC-LCIS (28 (44%)), followed by CIS (18 (29%)), V-LCIS (14 (22%)) and P-LCIS (3 (5%)). On core biopsy, 36/44 (82%) of NC-LCIS cases were E-cadherin negative, 38/41 (93%) were ER positive, and 6/34 (18%) were HER2 positive. IC and/or DCIS were diagnosed on subsequent surgery in 22 (33%) of patients, of which 14 (67%) were IC and 8 (18%) had DCIS only.
LesionTotalE-cadherin negativeUpgraded, N (%)Invasive cancer, N (%)DCIS only, N (%)CIS188/10 (80%)3 (16%)2 (67%)1 (33%)CIS/DLF2819/23 (83%)12 (43%)7 (58%)5 (42%)P-LCIS31/1 (100%)3 (100%)2 (67%)1 (33%)V-LCIS148/10 (80%)4 (29%)3 (75%)1 (25%)
Median IC size was 0.2 cm (0.06-1.1 cm). IC histology was ductal in n=4 (29%), lobular in n=7 (50%), and ductal and lobular in n=3 (21%). Among the 14 invasive lesions, 5 (36%) were grade I, 5 (36%) were grade II and 2(13%) were grade III, (grade was not reported for 2 remaining ICs); 12/14 (86%) were ER positive and 1/14 (7%) was HER2 positive; none had LVI or positive nodes.
Among the 42 cases not upgraded, 13 (31%) had mastectomy, 9 (21%) had excision and radiation, 20 had excision only, all had negative margins. At median follow-up of 60 months (1-224 months), 1/20 patients treated with excision only was diagnosed with DCIS, 14 months after surgery for CIS/DLF on core biopsy.
Conclusions: In this large series of NC-LCIS diagnosed on core biopsy, the upgrade rate to carcinoma was 33% supporting the recommendation for routine excision of these lesions. The cancers found at excision were all stage I and the majority were grade I or II. At a median follow-up of 60 months only 1/20 patients with pure NC-LCIS treated with excision alone developed a future ipsilateral cancer. Further study of the natural history of these rare lesions is warranted.
Citation Format: Nakhlis F, Harrison BT, Lester SC, Hughes KS, Coopey SB, King TA. Evaluating the risk of upgrade to invasive breast cancer and/or DCIS on excision following a diagnosis of non-classic lobular carcinoma in situ [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-22-01.
Collapse
Affiliation(s)
- F Nakhlis
- Brigham and Women's Hospital, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - BT Harrison
- Brigham and Women's Hospital, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - SC Lester
- Brigham and Women's Hospital, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - KS Hughes
- Brigham and Women's Hospital, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - SB Coopey
- Brigham and Women's Hospital, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - TA King
- Brigham and Women's Hospital, Boston, MA; Massachusetts General Hospital, Boston, MA
| |
Collapse
|
3
|
Coopey SB, Mazzola E, Buckley JM, Sharko J, Belli AK, Kim EMH, Polufriaginof F, Parmigiani G, Garber JE, Smith BL, Gadd MA, Specht MC, Guidi AJ, Roche CA, Hughes KS. S4-4: Clarifying the Risk of Breast Cancer in Women with Atypical Breast Lesions. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-s4-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Women diagnosed with atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), and borderline ADH/DCIS are at increased risk for breast cancer, but the precise degree of risk varies widely in the literature. Information from prior studies is limited by grouping ADH and ALH together and by small cohort sizes.
Objectives: To identify women with a pathologic diagnosis of ADH, ALH, LCIS, and borderline ADH/DCIS using Natural Language Processing. To evaluate breast cancer risk based on atypia type.
Methods: Using Natural Language Processing, we reviewed all electronically available pathology reports from Massachusetts General Hospital, Brigham and Women's Hospital, and Newton-Wellesley Hospital (members of Partners HealthCare System) from 1987–2010. We identified all women with a diagnosis of ADH, ALH, LCIS, and borderline ADH/DCIS with no prior or concurrent diagnosis of breast cancer. We determined the incidence of subsequent invasive and noninvasive breast cancer, the side of cancer diagnosis compared to original atypia side, and the time to cancer diagnosis for each atypia type.
Results: We reviewed 76,333 path reports in 42,950 unique individuals and identified 3049 women who were diagnosed with atypical breast lesions over this 14-year period; 1233 (40.4%) had ADH, 851 (27.9%) had ALH, 595 (19.5%) had LCIS, and 370 (12.1%) had borderline ADH/DCIS. The mean age for atypia diagnosis was 51 years (range: 18–93). At a mean follow-up of 66 months, cancer occurred in 7.0% of women with ADH, 11.3% of women with ALH, 11.1% of women with LCIS, and 8.4% of women with borderline ADH/DCIS. The median time to breast cancer diagnosis was 48 months with ADH, 50 months with ALH, 47 months with LCIS, and 60 months with borderline ADH/DCIS. Significantly more ipsilateral cancers developed than contralateral cancers for all types of atypia combined (p=0.027).
The development of invasive versus noninvasive breast cancer was not significantly affected by atypia type. Subsequent cancers were DCIS in 121 patients (43.4%) and invasive in 158 patients (56.6%). Kaplan Meier curves for time to cancer diagnosis based on atypia type were created. The curves for ADH and borderline ADH/DCIS were similar and significantly different than the curves for ALH and LCIS (p<0.001). The estimated 5 and 10-year breast cancer risks for each atypia type are presented in Table 1.
Conclusion: A diagnosis of ADH, ALH, LCIS, or borderline ADH/DCIS increases a woman's risk of invasive and noninvasive breast cancer in either breast. The breast cancer risk at 5 and 10 years is significantly higher in those with ALH or LCIS compared to those with ADH or borderline ADH/DCIS, but there is little difference in risk between ADH and borderline ADH/DCIS or between LCIS and ALH.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr S4-4.
Collapse
Affiliation(s)
- SB Coopey
- 1Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Newton-Wellesley Hospital, Newton, MA; Wayne State University, Detroit, MI
| | - E Mazzola
- 1Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Newton-Wellesley Hospital, Newton, MA; Wayne State University, Detroit, MI
| | - JM Buckley
- 1Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Newton-Wellesley Hospital, Newton, MA; Wayne State University, Detroit, MI
| | - J Sharko
- 1Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Newton-Wellesley Hospital, Newton, MA; Wayne State University, Detroit, MI
| | - AK Belli
- 1Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Newton-Wellesley Hospital, Newton, MA; Wayne State University, Detroit, MI
| | - EMH Kim
- 1Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Newton-Wellesley Hospital, Newton, MA; Wayne State University, Detroit, MI
| | - F Polufriaginof
- 1Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Newton-Wellesley Hospital, Newton, MA; Wayne State University, Detroit, MI
| | - G Parmigiani
- 1Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Newton-Wellesley Hospital, Newton, MA; Wayne State University, Detroit, MI
| | - JE Garber
- 1Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Newton-Wellesley Hospital, Newton, MA; Wayne State University, Detroit, MI
| | - BL Smith
- 1Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Newton-Wellesley Hospital, Newton, MA; Wayne State University, Detroit, MI
| | - MA Gadd
- 1Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Newton-Wellesley Hospital, Newton, MA; Wayne State University, Detroit, MI
| | - MC Specht
- 1Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Newton-Wellesley Hospital, Newton, MA; Wayne State University, Detroit, MI
| | - AJ Guidi
- 1Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Newton-Wellesley Hospital, Newton, MA; Wayne State University, Detroit, MI
| | - CA Roche
- 1Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Newton-Wellesley Hospital, Newton, MA; Wayne State University, Detroit, MI
| | - KS Hughes
- 1Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Newton-Wellesley Hospital, Newton, MA; Wayne State University, Detroit, MI
| |
Collapse
|
4
|
Buckley JM, Coopey S, Samphao S, Specht MC, Hughes KS, Gadd M, Taghian AG, Smith BL. Recurrence rates and long-term survival in women diagnosed with breast cancer at age 40 and younger. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.70] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
70 Background: Young age at diagnosis of breast cancer has been reported to be an independent risk factor for disease recurrence. However, there is little data on long term survival of young patients. We present long term follow up of a large cohort of women diagnosed with breast cancer at age 40 and younger. We determined rates of loco-regional recurrence (LRR), distant recurrence, and overall survival and adjusted for the patient and tumor characteristics which potentially predict outcomes. Methods: Following Institutional Review Board approval, data from the medical records of 628 women diagnosed with breast cancer at age 40 or younger between 1996 and 2008 were collected. Survival curves were estimated using the Kaplan Meier method. Results: Median age was 37 years (range: 21-40) and median follow-up was 72 months (range: 5-177). The rates of LRR as a first site of recurrence were 5.56% at 5 years and 12.11% at 10 years. In the entire population, with median follow-up of 72 months, there was no difference in the rates of loco-regional failure between patients who underwent breast conserving therapy (7.34%) compared to mastectomy (7.40%) (p=0.980). The rates of distant recurrence as a first event were 10.65% at 5 years and 14.58% at 10 years. Overall survival was 93.1% at 5 years and 87.26% at 10 years. 79.1% of patients received systemic therapy. For patients who developed disease recurrence, either LRR or distant, median time to first recurrence was 35 months (range: 3-167). Conclusions: Women aged 40 and younger at diagnosis of breast cancer have a good prognosis, with low overall recurrence rates at 5 and 10 years. Local recurrence in our cohort is lower than in prior studies, suggesting advances in therapy have made breast conservation a safe option in young breast cancer patients.
Collapse
Affiliation(s)
| | - S. Coopey
- Massachusetts General Hospital, Boston, MA
| | - S. Samphao
- Massachusetts General Hospital, Boston, MA
| | | | | | - M. Gadd
- Massachusetts General Hospital, Boston, MA
| | | | | |
Collapse
|
5
|
Hughes KS, Schnaper LA, Cirrincione C, Berry DA, McCormick B, Muss HB, Shank B, Hudis C, Winer EP, Smith BL. Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.507] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
6
|
Kim E, Sharko J, Drohan B, Roche C, Specht M, Gadd M, Smith BL, Hughes KS. Breast cancer and high-risk diagnosis in core biopsies stratified by ethnicity. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Ozanne EM, Sharko J, Drohan B, Grinstein G, Hughes KS. Identification of high-risk lesions through automated natural language processing (NLP) of pathology reports. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-3001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #3001
Purpose
 Pathology reports contain extensive research information that is inaccessible except through costly and time consuming chart reviews. This is due to the fact that pathology reports are recorded as semi-structured prose with critically important descriptive text intended for human interpretation. Key challenges for processing this data include interpreting multiple methods of describing the same finding, and subsequently aggregating the findings of multiple reports into episodes of care. Investigators tested NLP techniques in the processing of pathology reports into structured data and episodes of care, allowing for the rapid identification and epidemiologic modeling of high-risk breast lesions.
 Methods
 Using state-of-the-art NLP software (ClearForest, A Thomson Reuters Company, Waltham, MA), breast pathology reports stored as text files were processed into a structured electronic database using these steps: 1) identification of diagnosis of interest (i.e. high risk lesions, cancer), 2) use of NLP to identify all terms and phrases used to report each finding (e.g. atypical hyperplasia, hyperplasia with atypia), 3) grouping of relevant terms into categories, 4) identification of categories occurring in each patient report, and 5) grouping of patient reports into episodes of care (defined as all reports within 6 months of an initial diagnosis).
 Results
 Under IRB approval, 27,931 breast pathology reports from Massachusetts General Hospital in 16,208 patients seen between 1990-2007 were analyzed. The results were compared against manually reviewed pathology reports for quality control. For DCIS diagnoses, the initial error rate for both the NLP process and the manual process was 2%. The NLP process was then re-tuned using the identified discrepancies which reduced the error rate to zero. Using the refined model, we identified 1) patients with atypical lesions (atypical ductal hyperplasia (ADH), severe ADH, atypical lobular hyperplasia (ALH), and lobular carcinoma in situ (LCIS)) without prior or concurrent cancer, and 2) patients who developed cancer greater than 6 months post diagnosis.
 
 Conclusion
 This process successfully identified high-risk diagnoses that were otherwise relatively inaccessible, and appears to match the accuracy of a human research associate. The results of this first implementation are promising and will be further validated over time. In the future, this approach can be applied to other medical reports and diseases. NLP has significant potential to decrease the cost of research and for improving patient care.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3001.
Collapse
Affiliation(s)
- EM Ozanne
- 1 Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA
- 2 Harvard Medical School, Boston, MA
| | - J Sharko
- 3 Computer Science Department, University of Massachusetts, Lowell, MA
| | - B Drohan
- 3 Computer Science Department, University of Massachusetts, Lowell, MA
| | - G Grinstein
- 3 Computer Science Department, University of Massachusetts, Lowell, MA
| | - KS Hughes
- 2 Harvard Medical School, Boston, MA
- 4 Avon Breast Evaluation Center, Massachusetts General Hospital, Boston, MA
| |
Collapse
|
8
|
Kirstein LJ, Martei Y, Roche C, Smith BL, Specht MC, Gadd MA, Drohan B, Lawrence C, Michaelson J, Hughes KS. LCIS and tamoxifen use: A single institution review. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1527] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1527 Background: Results of the NSABP-P1 trial were published in 1998 showing a 50% reduction in breast cancer in the high- risk population with the use of tamoxifen. The use of tamoxifen is individualized, and depends on both patient and physician factors. We looked at the recommendations for and the use of tamoxifen in women with LCIS. Methods: A retrospective chart review at a single institution was performed from March 27, 1980 through September 19, 2005 for patients diagnosed with LCIS. Pathology and operative reports, as well as patient notes were reviewed for discussions about tamoxifen. Data was collected on whether a discussion took place, whether tamoxifen was or was not advised, whether the patient declined to take tamoxifen, whether they took it in the past or were currently on tamoxifen. We also examined the rate of DCIS and invasive cancer in this population. Results: There were 321 patients diagnosed with LCIS. Of those patients 193 were diagnosed after the publication of the P1 trial. Of these 193 patients we identified 104(54%) patients whose charts contained notes indicating a discussion about tamoxifen. The results of the discussion about tamoxifen are as follows: 21(20%) patients were currently taking tamoxifen, 16(15%) had taken it in the past, 37(36%) patients declined to take tamoxifen, and 17(16%) had not made a decision about taking tamoxifen. There were 13(13%) patients for whom tamoxifen was advised against. In the entire cohort of 321 patients, 15% went on to develop DCIS or invasive cancer in the first 12 years of follow up. We did not look at cancer rate Vs tamoxifen use due to the small numbers with available information. Conclusions: While the P1 trial recommends tamoxifen for breast cancer prevention in high-risk patients, in our experience, almost half of the patients did not have a documented discussion about the medication, and the majority of those who did decided not to take tamoxifen. This will likely have a large impact on the rate of DCIS and invasive breast cancer in this group. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - Y. Martei
- Massachusetts General Hospital, Boston, MA
| | - C. Roche
- Massachusetts General Hospital, Boston, MA
| | | | | | - M. A. Gadd
- Massachusetts General Hospital, Boston, MA
| | - B. Drohan
- Massachusetts General Hospital, Boston, MA
| | | | | | | |
Collapse
|
9
|
Alm El-Din MA, Hughes KS, Goldberg SI, Raad RA, Taghian AG. Breast cancer after treatment of Hodgkin disease: Clinical outcome of 38 cases in 27 patients. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.11059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11059 Background: Many studies showed that women who are cured of HD have an increased risk of developing BC. Our purpose is to evaluate detection, pathology, management and prognosis of BC occurring after HD. Methods: Thirty-eight cases of BC in 27 survivors of HD were analyzed. All patients received supradiaphragmatic RT and 13 had also chemotherapy for HD. Results: The median age of the patients at diagnosis of HD was 25.5 years. The median interval to develop BC was 15.9 years. The median age at diagnosis of BC was 45.8 years. Ten women (37%) had bilateral disease; one of them had DCIS, 7 years before developing bilateral disease. Cancers were detected by mammography (59.4%), symptom presentation (24.3%), clinical examination (8%), and incidental during elective mastectomy (8%). Using Fisher’s Exact test, DCIS was more frequent (27%), where nodal involvement (29.6%), and ER positivity (81.5%) were paralleled that reported in general population. Thirty tumors (79%) were managed by mastectomy due to prior RT. Two women received RT following mastectomy. Eight tumors treated by lumpectomy, followed by RT in two women; one received whole breast RT, while the other received fractionated partial breast irradiation using 3D-conformal technique (50Gy/25 fractions) and she is doing well 1 1/2 years after RT. Adjuvant systemic therapy, given to 17 patients, was well tolerated. The median follow-up after BC was 61 months. Using Kaplan-Maier procedure, the 6-year actuarial relapse-free survival for node-negative BC after HD was 100%. Node positive patients had a significantly lower RFS of 58.3% ± 19% (P = 0.01). Conclusions: Compared to patients with primary BC, patients developing BC after HD are more likely to be younger, have bilateral disease and have more frequent DCIS. Other pathological features and prognosis are similar to that reported in general population. Patient awareness, breast examination and mammography should be part of the follow-up program for HD survivors. Mastectomy remains the standard of care in most of cases; however, lumpectomy followed by fractionated partial breast irradiation might be a reasonable approach to investigate for women who refuse mastectomy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - K. S. Hughes
- Massachusetts General Hosp, Harvard Medical School, Boston, MA
| | - S. I. Goldberg
- Massachusetts General Hosp, Harvard Medical School, Boston, MA
| | - R. A. Raad
- Massachusetts General Hosp, Harvard Medical School, Boston, MA
| | - A. G. Taghian
- Massachusetts General Hosp, Harvard Medical School, Boston, MA
| |
Collapse
|
10
|
Jones JL, Rhei E, Gadd MA, Howard-Mcnatt M, Hughes KS, Lesnikoski BA, Christian RL, Rabban JT, Kaelin C, Smith BL. Predictive value of sentinel lymph node biopsy prior to neoadjuvant chemotherapy in clinically node negative breast cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.606] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. L. Jones
- Massachusetts General Hospital, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - E. Rhei
- Massachusetts General Hospital, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - M. A. Gadd
- Massachusetts General Hospital, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - M. Howard-Mcnatt
- Massachusetts General Hospital, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - K. S. Hughes
- Massachusetts General Hospital, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - B.-A. Lesnikoski
- Massachusetts General Hospital, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - R. L. Christian
- Massachusetts General Hospital, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - J. T. Rabban
- Massachusetts General Hospital, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - C. Kaelin
- Massachusetts General Hospital, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - B. L. Smith
- Massachusetts General Hospital, Boston, MA; Brigham and Women's Hospital, Boston, MA
| |
Collapse
|
11
|
Rieger-Christ KM, Pezza JA, Dugan JM, Braasch JW, Hughes KS, Summerhayes IC. Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas. Mol Pathol 2001; 54:91-7. [PMID: 11322170 PMCID: PMC1187009 DOI: 10.1136/mp.54.2.91] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
AIMS The relation between lobular carcinoma in situ (LCIS) and invasive breast cancer is unresolved. In an attempt to establish whether LCIS is a precursor of invasive cancer the mutational status and the expression of E-cadherin was analysed in LCIS and associated invasive breast carcinoma in 23 patients. METHODS Foci of LCIS and associated invasive carcinoma were individually microdissected from tissue from 23 patients. Exons 4-16 of the E-cadherin gene were analysed using single strand conformation polymorphism (SSCP); protein expression and the localisation of E-cadherin and beta-catenin were assessed with the use of immunohistochemistry. RESULTS Immunohistochemistry revealed a lack of expression of E-cadherin and beta-catenin in most LCIS samples and invasive foci. In all but four cases, the staining pattern was identical in the LCIS and associated invasive areas. When E-cadherin was absent, beta-catenin was also undetected, suggesting a lack of expression of alternative classic cadherin members in these lesions. Coincident E-cadherin mutations in LCIS and associated invasive carcinoma were not identified in this series of patients. However, mutational analysis of E-cadherin in multiple foci of carcinoma in situ surrounding an invasive lesion provided evidence to support ductal carcinoma in situ as a precursor of invasive ductal carcinoma. CONCLUSION These data support the hypothesis that LCIS is not a precursor of invasive breast carcinoma but a marker of increased risk of developing invasive disease.
Collapse
Affiliation(s)
- K M Rieger-Christ
- Cell and Molecular Biology Laboratory, Robert E Wise Research and Education Institute, Burlington, MA 01805, USA.
| | | | | | | | | | | |
Collapse
|
12
|
Schnaper LA, Hughes KS. Special considerations when treating breast cancer in the elderly. Breast Dis 2001; 12:83-93. [PMID: 15687609 DOI: 10.3233/bd-2001-12109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
The growing aging population of the U.S. will lead to an absolute and proportional increase in elderly women with breast cancer. While the underlying biologic characteristics of the disease will not likely change, the health status and life expectancy of the patients will improve. Our decisions regarding therapy must take into account not just the disease we are treating, but the characteristics of the host as well.
Collapse
Affiliation(s)
- L A Schnaper
- Comprehensive Breast Care Center, Greater Baltimore Medical Center, Baltimore, MD, USA
| | | |
Collapse
|
13
|
Abstract
Epidemiologic studies have provided information on risk factors for breast cancer. Gail and associates identified five risk factors using the Breast Cancer Detection Demonstration Project (BCDDP) population and developed a model to calculate a composite relative risk (RR). This model is commonly used to counsel women regarding their risk for breast cancer and was used by the National Surgical Adjuvant Breast Project (NSABP) for eligibility for the Breast Cancer Prevention Trial. Because the BCDDP population was composed almost entirely of women 40 years of age or older, our purpose was to evaluate the effectiveness of the Gail model in estimating the risk of breast cancer for women under 40 in the clinical setting. The Gail risk factors were assessed for 124 patients under the age of 40 treated for either ductal carcinoma in situ (DCIS) or invasive breast cancer at the Lahey Hitchcock Medical Center between 1983 and 1995. The RR was calculated using the Gail model. For comparison, two cohorts of women under the age of 40 were used: 107 randomly selected patients who underwent a breast biopsy because of a benign condition and 129 nurses from our institution who responded to a questionnaire that included reproductive and family history information as used in the Gail model. The RR calculated was the RR that existed at the time of the surgical consultation for a suspicious breast lesion. The Tarone-Ware method was used to analyze statistical significance of differences between distribution. Contingency tables were analyzed using Miettinen's modification of Fisher's exact test. No differences were found between the median RR for all groups. Only 2 of the 124 patients with breast cancer had a RR of 5 or more (the RR required to enter the Breast Cancer Prevention Trial). The distribution of age at menarche (AGEMEN) was the same for each group. No difference was found for the distribution of age at first live birth (AGEFLB) between those with breast cancer and those with a benign biopsy or the control group. The number of breast biopsies (NBIOPS) was higher in patients with a benign breast biopsy. No difference was found in the distribution of number of first-degree relatives with breast cancer (NUMREL). Overall the Gail model failed to differentiate those women about to have cancer diagnosed from two control populations. The Gail model is not useful in identifying immediate risk of breast cancer in women under 40 and should not be used for that purpose.
Collapse
Affiliation(s)
- G MacKarem
- Breast Cancer Treatment Center and the Department of General Surgery, Lahey Hitchcock Medical Center, Burlington, Massachusetts, USA
| | | | | |
Collapse
|
14
|
Abstract
Breast cancer management requires a multidisciplinary approach that is tailored to the patient's stage at presentation, desire for breast conservation or reconstruction, estimation of risk of recurrence, and assessment of the benefits and toxicities of potential adjuvant therapies. At the Lahey Clinic Medical Center, breast surgeons, plastic surgeons, radiation oncologists, and medical oncologists staff the Breast Cancer Treatment Clinic, and work closely together to formulate treatment plans that will optimize the likelihood for cure with an acceptable cosmetic result. This involves careful preoperative work-up, surgical axillary staging, breast irradiation in the setting of breast conservation, and selection of chemotherapy or hormonal therapy if appropriate. Newer aspects of breast cancer care, including sentinal lymph node biopsy, postmastectomy radiation therapy, expanded use of hormonal therapy in younger women, new agents and chemotherapy combinations, and autogenous reconstruction techniques, have become an essential part of the multidisciplinary clinic approach.
Collapse
|
15
|
Abstract
Relative to her risk of breast carcinoma, the woman with a BRCA1 or BRCA2 gene mutation can be managed either by intensive screening (with or without chemoprevention) or by prophylactic mastectomy. Although it would be preferable to avoid prophylactic surgery, the current level of screening technology and the rudimentary state of chemoprevention do not guarantee a good outcome with intensive surveillance. A review of the currently available data was undertaken to determine the efficacy of prophylactic surgery, intensive screening, and chemoprevention. An attempt then was made to extrapolate the efficacy of the various approaches to the management of women who carry BRCA1 or BRCA2 gene mutations. Intensive surveillance may not detect breast carcinoma at an early, curable stage in young women with BRCA1 or BRCA2 gene mutations because the growth rate of the tumors in these women most likely will be rapid and the density of the breast tissue may compromise detection. Chemoprevention is in its infancy, and its efficacy in this population is unknown. Conversely, prophylactic surgery may not be completely effective in preventing breast carcinoma. The authors are hopeful that sometime in the next decade advances in chemoprevention, screening technology, or breast carcinoma treatment will make mastectomy obsolete. However, for the time being prophylactic mastectomy has attributes that make it an alternative for this population that must be considered. Careful discussion of all options is essential in the management of these women.
Collapse
Affiliation(s)
- K S Hughes
- Risk Assessment Clinic, Lahey Clinic, Peabody, Massachusetts 01960, USA
| | | | | | | |
Collapse
|
16
|
Marsh DJ, Dahia PL, Caron S, Kum JB, Frayling IM, Tomlinson IP, Hughes KS, Eeles RA, Hodgson SV, Murday VA, Houlston R, Eng C. Germline PTEN mutations in Cowden syndrome-like families. J Med Genet 1998; 35:881-5. [PMID: 9832031 PMCID: PMC1051477 DOI: 10.1136/jmg.35.11.881] [Citation(s) in RCA: 118] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Cowden syndrome (CS) or multiple hamartoma syndrome (MIM 158350) is an autosomal dominant disorder with an increased risk for breast and thyroid carcinoma. The diagnosis of CS, as operationally defined by the International Cowden Consortium, is made when a patient, or family, has a combination of pathognomonic major and/or minor criteria. The CS gene has recently been identified as PTEN, which maps at 10q23.3 and encodes a dual specificity phosphatase. PTEN appears to function as a tumour suppressor in CS, with between 13-80% of CS families harbouring germline nonsense, missense, and frameshift mutations predicted to disrupt normal PTEN function. To date, only a small number of tumour suppressor genes, including BRCA1, BRCA2, and p53, have been associated with familial breast or breast/ovarian cancer families. Given the involvement of PTEN in CS, we postulated that PTEN was a likely candidate to play a role in families with a "CS-like" phenotype, but not classical CS. To answer these questions, we gathered a series of patients from families who had features reminiscent of CS but did not meet the Consortium Criteria. Using a combination of denaturing gradient gel electrophoresis (DGGE), temporal temperature gel electrophoresis (TTGE), and sequence analysis, we screened 64 unrelated CS-like subjects for germline mutations in PTEN. A single male with follicular thyroid carcinoma from one of these 64 (2%) CS-like families harboured a germline point mutation, c.209T-->C. This mutation occurred at the last nucleotide of exon 3 and within a region homologous to the cytoskeletal proteins tensin and auxilin. We conclude that germline PTEN mutations play a relatively minor role in CS-like families. In addition, our data would suggest that, for the most part, the strict International Cowden Consortium operational diagnostic criteria for CS are quite robust and should remain in place.
Collapse
Affiliation(s)
- D J Marsh
- Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115-6084, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Hughes KS, Barbarisi LJ, Rossi RL, Walsh J, deCrescenzo N. Using continuous quality improvement (CQI) to improve the care of patients with breast cancer. Adm Radiol J 1997; 16:19-20, 26-7. [PMID: 10170268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Affiliation(s)
- K S Hughes
- Breast Cancer Treatment Center, Lahey Hitchcock Medical Center, Burlington, MA, USA
| | | | | | | | | |
Collapse
|
18
|
Abstract
OBJECTIVE To examine options of management and outcome of twin pregnancies discordant for anencephaly. DESIGN Retrospective study. SETTING Research Centre for Fetal Medicine. POPULATION Twenty-four twin pregnancies discordant for anencephaly. METHODS A computer search was made of our database for twin pregnancies discordant for anencephaly. The data were reviewed for gestation at presentation, chorionicity, management and pregnancy outcome. MAIN OUTCOME MEASURES Pregnancy outcome in relation to chorionicity and management. RESULTS There were 13 dichorionic and 11 monochorionic twin pregnancies discordant for anencephaly. In the dichorionic group five pregnancies had selective fetocide at 17 to 21 weeks; one pregnancy resulted in spontaneous abortion but in the others a healthy infant was born at a median gestation of 37 weeks. The other eight dichorionic pregnancies were managed expectantly, but three developed polyhydramios at 26 to 30 weeks; in one case amniodrainage was performed and in another selective fetocide was carried out. In this group the median gestation at delivery was 35 weeks. All 11 monochorionic pregnancies were managed expectantly and in three there was intrauterine death of both fetuses. In the other eight cases the normal twin was liveborn at a median gestation of 34 weeks; in four of these pregnancies polyhydramnios developed and two were managed by amniodrainage. CONCLUSIONS In monochorionic pregnancies, expectant management is associated with a high rate of intrauterine lethality of the normal twin. In dichorionic pregnancies selective fetocide in the second trimester prevents the development of polyhydramnios and is associated with a lower risk of preterm delivery but can cause miscarriage.
Collapse
Affiliation(s)
- N J Sebire
- Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, Medical School, London, UK
| | | | | | | | | |
Collapse
|
19
|
Abstract
Breast cancer is the most common cancer in women and is the second (after lung cancer) leading cause of cancer deaths in women. Knowledge of breast cancer and its epidemlology, natural course, and response to treatment continue to evolve, making the survival rates for patients with breast cancer more optimistic. Women with breast cancer must decide, in partnership with expert physicians and nurses, what their options are for screening, diagnosis, and treatment. This article provides an overview of options available to women diagnosed with breast cancer.
Collapse
Affiliation(s)
- J Buyske
- Lahey Hitchcock Medical Center, Burlington, Mass, USA
| | | | | | | |
Collapse
|
20
|
|
21
|
Abstract
In summary, certain subgroups of DCIS appear not to require radiation. Corroboration of these results from retrospective reviews and prospective trials is necessary to confirm the safety and efficacy of individualized treatment strategies. Even though the current standard of treatment is (1) lumpectomy with radiation therapy, (2) mastectomy, or (3) mastectomy with reconstruction, it is possible in the future to say that patients with low-grade DCIS (the exact criteria to be defined) may be eligible for breast conservation without radiation, and all patients with high-grade DCIS or perhaps low-grade DCIS with necrosis would be treated best by lumpectomy plus radiation. It is possible that a small subgroup of patients may be best treated by mastectomy, or perhaps, as the results of B-24 become available, by radiation therapy plus tamoxifen. The use of tumor markers such as c-erbB-2, cathepsin D, and NM 23 may help us to better define these subgroups, but much study is necessary before a definite treatment strategy is reached.
Collapse
Affiliation(s)
- K S Hughes
- Lahey-Hitchcock Breast Cancer Treatment Center, Burlington, MA 01805, USA
| | | | | |
Collapse
|
22
|
Abstract
BACKGROUND Although breast cancer in men is far less common than breast cancer in women, it is associated with a less favorable prognosis. Conventional histopathologic features and new prognostic markers were evaluated to explain the less favorable survival outcome. METHODS Forty-six consecutive male breast carcinomas were studied for size, histologic and nuclear grade, histologic subtype, presence of carcinoma in situ, nipple involvement, lymphovascular invasion, hormone receptor status, c-erbB-2 protein overexpression, and p53 protein accumulation. These findings were correlated with survival. RESULTS Of the 46 carcinomas, 4 were noninvasive and 42 were invasive. In the invasive carcinomas, the median patient age was 64 years, and the median tumor size was 2 cm. The predominant histologic patterns were invasive ductal (45%) and mixed invasive ductal and cribriform (28%). Most tumors were of low histologic and nuclear grades (histologic grades: I, 17%; II, 50%; III, 33%; nuclear grade: I, 12%; II, 44%; III, 44%). Of those surgically staged, 22 patients (60%) were lymph node positive and 15 patients (40%) were node negative. Stage at presentation was higher than in women (0, 10%; 1, 17%; 2, 50%; 3, 13%; 4, 10%). The estrogen and progesterone receptor status was positive in 76% and 83% of tumors, respectively. Lymphatic vessel invasion (63%) and nipple involvement (48%) were also more common than in women. True Paget's disease of the nipple was not seen; all cases with nipple ulceration were the result of direct tumor extension to the epidermis. Of the 17 tumors tested, 41% were c-erbB-2 positive and 29% were p53 positive. Survival analysis was limited by the relatively small cohort size. Five- and 10-year adjusted overall survival rates for invasive tumors were 76 +/- 7% and 42 +/- 9%, respectively. Skin and nipple involvement (P = 0.03) and c-erbB-2-positivity (P = 0.03) were significant predictors of adverse survival. CONCLUSIONS Male breast carcinoma presents in an advanced stage with less favorable survival, despite low histologic grade, high estrogen receptor content, and small size. Anatomic factors may have been responsible for the poor survival outcome (i.e., paucity of breast tissue and close tumor proximity to skin and nipple, facilitating dermal lymphatic spread and early regional and distant metastasis).
Collapse
MESH Headings
- Adenocarcinoma/mortality
- Adenocarcinoma/pathology
- Age Factors
- Breast Neoplasms, Male/chemistry
- Breast Neoplasms, Male/mortality
- Breast Neoplasms, Male/pathology
- Carcinoma, Ductal, Breast/mortality
- Carcinoma, Ductal, Breast/pathology
- Humans
- Lymphatic Metastasis
- Male
- Middle Aged
- Nipples/pathology
- Prognosis
- Receptor, ErbB-2/analysis
- Receptors, Estrogen/analysis
- Receptors, Progesterone/analysis
- Survival Rate
Collapse
Affiliation(s)
- M G Joshi
- Department of Anatomic Pathology, Lahey Hitchcock Medical Center, Burlington, Massachusetts 01805, USA
| | | | | | | | | | | | | |
Collapse
|
23
|
Joshi MG, Lee AK, Pedersen CA, Schnitt S, Camus MG, Hughes KS. The role of immunocytochemical markers in the differential diagnosis of proliferative and neoplastic lesions of the breast. Mod Pathol 1996; 9:57-62. [PMID: 8821958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The differential expression of keratins in myoepithelial and epithelial cells of the breast makes immunohistochemical distinction of lesions an attractive possibility. High molecular weight keratin, 34BE12, is a monoclonal antibody that recognizes keratins 1, 5, 10, and 14. Because myoepithelial cells predominantly express keratins 5 and 14 and epithelial cells predominantly express keratins 8 and 18, it is natural to assume that 34BE12 may be a good marker of myoepithelial cells but not epithelial cells. However, recent studies of the breast have reported conflicting results. To determine the potential role of 34BE12 in the breast, we studied by immunohistochemistry 19 tubular carcinomas, 14 radial scars, two microglandular adenoses, and 9 sclerosing adenoses, using monoclonal antibodies to high molecular weight keratin, smooth muscle actin, type IV collagen, and antiserum to S100 protein. Actin was negative in all 19 (100%) tubular carcinomas, but it delineated the myoepithelial cells in 22 of 23 (95.6%) benign lesions of sclerosing adenosis and radial scars; it was also negative in microglandular adenosis. In comparison, epithelial cytoplasmic 34BE12 reactivity was seen in 3 of 19 (15.8%) tubular carcinomas, whereas myoepithelial cells failed to react in 4 of 23 (17.3%) benign conditions. Antiserum to S100 protein had a similar disadvantage of labeling both epithelial and myoepithelial cells with reactivity in 5 of 19 (26.3%) tubular carcinomas. In microglandular adenosis, the epithelial cells were strongly S100 protein positive and focally 34BE12 positive, but no staining was observed for actin. Type IV collagen staining outlined distinct basement membranes in microglandular adenosis and other benign conditions but not in tubular carcinomas. However, staining for type IV collagen requires enzymatic pretreatment and is difficult to perform, especially in sclerotic breast tissue. In conclusion, actin appears to be the most consistent and specific marker for distinguishing tubular carcinomas from other benign conditions, and type IV collagen has a contributory role, whereas 34BE12 is less valuable than in prostatic biopsies.
Collapse
Affiliation(s)
- M G Joshi
- Department of Anatomic Pathology, Lahey Clinic, Burlington, MA 01805, USA
| | | | | | | | | | | |
Collapse
|
24
|
Abstract
BACKGROUND Ductal carcinoma in situ (DCIS) of the male breast is an uncommon disease, accounting for approximately 7% of all male breast carcinomas. Compared with invasive carcinomas of the breast, the prognosis associated with DCIS in men is excellent; however, clinical features, pathology, and treatment of this disease are not well defined in the literature. METHODS Records of 23 men with carcinoma of the breast treated at the Lahey Clinic from 1968 to 1991 were reviewed, revealing 4 patients with pure DCIS (17%). The reported management of DCIS in women is discussed in comparison with that of DCIS in men. RESULTS Of the four patients with DCIS, the presenting complaint was a retroareolar mass in three patients and a bloody nipple discharge in one patient. The pathologic subtype was papillary in one patient and intracystic papillary in three patients. Two patients were treated with partial mastectomy alone. Disease recurred locally as DCIS in both patients, requiring mastectomy at 30 and 108 months. No lymph node metastases were found in the three patients who underwent axillary dissection. All four patients were alive without disease at 133, 120, 36, and 32 months of follow-up, respectively. CONCLUSIONS Although the sample size was small, our patients and a review of the literature suggest that most DCIS in men is of the papillary type and that mastectomy without axillary dissection is the preferred treatment.
Collapse
MESH Headings
- Adenocarcinoma/pathology
- Adult
- Aged
- Aged, 80 and over
- Breast Neoplasms/pathology
- Breast Neoplasms/surgery
- Carcinoma in Situ/pathology
- Carcinoma in Situ/surgery
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Ductal, Breast/surgery
- Carcinoma, Papillary/pathology
- Female
- Follow-Up Studies
- Humans
- Male
- Mastectomy, Modified Radical
- Mastectomy, Radical
- Mastectomy, Segmental
- Mastectomy, Simple
- Middle Aged
- Neoplasm Invasiveness
- Neoplasm Staging
- Sex Factors
- Treatment Outcome
Collapse
Affiliation(s)
- M G Camus
- Department of General Surgery (Surgical Oncology), Lahey Clinic, Burlington, Massachusetts 01805
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
|
26
|
Tsao JI, Asbun HJ, Hughes KS, Abaubara S, August DA, Azurin A, Braasch JW, Broelsh C, Cady B, Chang AE. Hepatoma registry of the Western world. Repeat Hepatic Resection Registry. Cancer Treat Res 1994; 69:21-31. [PMID: 8031652 DOI: 10.1007/978-1-4615-2604-9_3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
The western HCC registry comprised data from 322 patients who underwent hepatic resection for HCC over a 50-year period. The majority of patients had lesions > 4 cm and were symptomatic at presentation. Lesions were mostly unicentric. Cirrhosis was not a prevalent problem, unlike the East. In the most recent decade, 1980-1989, we noted a significant decrease in operative mortality from 19% to 10% overall, and 15% to 4% in the noncirrhotic group. We identified four variables that resulted in poorer postresectional outcome: cirrhosis, regional nodal disease, multicentric disease, and tumor-free resectional margin < 1 cm. Although these factors are associated with a poorer outcome after resection, whether they should serve as contraindications to surgery should be determined by individual surgeons, taking into account the patient's overall status, concomitant risk factors, and treatment objectives.
Collapse
Affiliation(s)
- J I Tsao
- Lahey Clinic, Burlington, MA 01805
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Affiliation(s)
- B Detroz
- Centre Hospitalier Universitaire de Liege, Service de Chirurgia Abdominale et Generale, Domaine Universitaire du Sart Tilman, Belgium
| | | | | | | | | |
Collapse
|
28
|
Abstract
When liver metastases from colorectal carcinoma are detected, the surgeon must decide whether or not the patient is a candidate for resection. Even though long-term survival after resection is far from optimal, the relegation of patients to nonresective treatment means denying them the only chance for cure currently available. Better understanding of liver anatomy and improvement in resection techniques have decreased the morbidity and mortality. The RHM and the GITSG reports have better defined the prognostic factors for resections of colorectal liver metastases and allowed for a better understanding of the indications for resection. During the last decades, liver resection has been extended to older patients, patients with multiple liver lesions, and patients with larger solitary metastases. At the same time, anatomic rather than wedge resections are more common, and it is preferable to perform the colon and liver resection at different stages. The end result has been a marked increase in the number of hepatic resections performed for colorectal liver metastases during the last two decades.
Collapse
|
29
|
Abstract
When metastatic or recurrent disease from colorectal carcinoma is detected, the surgeon must decide whether a patient is a candidate for resection. Although long-term survival after resection is not optimal, the relegation of patients to nonresective treatment means denying them the only chance for cure currently available. When isolated disease involving the liver, lung, or region of the primary carcinoma is documented, curative resection must be considered. Symptomatic patients may also obtain maximal palliation from resection, diversion, or a bypass procedure. Chemotherapy for the treatment of recurrent disease is palliative and probably should be considered only within clinical trials. Future alternative methods of treatment or new chemotherapeutic regimens need to be studied to improve survival and quality of life.
Collapse
Affiliation(s)
- H J Asbun
- Department of General Surgery, Lahey Clinic Medical Center, Burlington, Massachusetts
| | | |
Collapse
|
30
|
Abstract
The pace of change in hepatobiliary surgery requires a sound foundation in basic surgical principles. Further reductions in morbidity and mortality rates and appropriate use of alternative therapies require careful attention to preoperative risk assessment and patient selection. To operate safely and successfully on the liver and bile ducts, the surgeon must be well versed in normal and variant hepatobiliary anatomy, understand the underlying disease and therapeutic alternatives, and known techniques of reoperative biliary surgery. Surgeons who operate on the gallbladder must be prepared to confront a host of unexpected and difficult operative problems. Bile duct injuries must be repaired properly at the first attempt. Complex biliary operations require a great level of technical expertise and judgment to obtain successful results and should only be undertaken by experienced hepatobiliary surgeons. As proficiency with the more routine procedures improves, increasingly complex and extensive procedures become possible. We must constantly police ourselves to be certain that these more extensive procedures truly benefit our patients.
Collapse
Affiliation(s)
- W J Schirmer
- Department of General Surgery, Lahey Clinic Medical Center, Burlington, Massachusetts
| | | | | | | | | |
Collapse
|
31
|
Levitan N, Hughes KS. Management of non-resectable liver metastases from colorectal cancer. Oncology (Williston Park) 1990; 4:77-84; discussion 84, 89, 92. [PMID: 2150329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Among patients who develop recurrent cancer following resection of the colorectal primary, 60-80% develop liver metastases. For such patients, liver resection is the only treatment that offers the potential for cure. Patients with four or fewer liver metastases and no apparent extrahepatic disease should be considered for resection. Patients with non-resectable liver metastases who are asymptomatic may prefer to receive no treatment until such time as symptoms occur. Those with symptomatic or rapidly progressive disease may be offered a variety of treatment approaches: Systemic chemotherapy (20% response rate); hepatic artery infusion; portal vein infusion; intraperitoneal chemotherapy; hepatic resection plus regional chemotherapy; hepatic artery ligation; hepatic artery ligation plus portal vein chemotherapy, and others. The advantages and disadvantages of each are discussed.
Collapse
Affiliation(s)
- N Levitan
- Department of General Surgery, Lahey Clinic Medical Center
| | | |
Collapse
|
32
|
Morse ED, Gunther RA, Jesmok GJ, Hughes KS. Steroid pretreatment reduces interleukin-2 toxicity in sheep. Surgery 1990; 107:639-47. [PMID: 2353306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Recombinant interleukin-2 (rIL-2) has shown promise in the treatment of patients with advanced cancer. However, toxicity of this therapy remains a major problem with its use in some patients. In this study we examined whether steroids could reduce the adverse cardiopulmonary effects of rIL-2. Seven sheep were surgically prepared with vascular catheters and lung lymph fistulas. Each sheep received either a single dose of rIL-2 (100 micrograms/kg) or rIL-2 plus methylprednisolone (30 mg/kg) followed by the reverse treatment 1 week later. Lung lymph flow increased markedly after rIL-2 with a peak QL of 140% +/- 30% (above baseline). Steroid pretreatment significantly reduced this lymph flow increase with peak lung lymph flow being only 40% +/- 16% (p less than 0.004). The lymph/plasma protein ratio tended to increase after rIL-2, but these changes were not statistically significant. After rIL-2, cardiac output, heart rate, core temperature, and mean pulmonary artery pressure increased (p less than 0.05), whereas systemic vascular resistance and arterial PO2 decreased (p less than 0.05). These changes did not occur with steroid pretreatment. The results of this study demonstrate that steroids reduced the adverse cardiopulmonary effects of rIL-2. We believe that rIL-2 induces activation of arachidonic acid metabolism, which leads to the production of multiple inflammatory mediators that cause increased microvascular permeability and the adverse cardiopulmonary effects of rIL-2.
Collapse
Affiliation(s)
- E D Morse
- Department of Surgery, University of California, Davis Medical Center, Sacramento 95817
| | | | | | | |
Collapse
|
33
|
Abstract
Hepatic resection is the only curative therapy currently available for colorectal cancer metastases to the liver. However, concern over high morbidity and mortality of the procedure has limited referral of patients for resection. The authors report on 58 patients undergoing hepatic resection for colorectal metastases at the National Cancer Institute between the years 1976 and 1985. Thirty-two patients underwent a major hepatic resection, and 26 patients underwent one or more wedge resections. Mean anesthesia time was 448 minutes, mean estimated blood loss was 3663 ml, and mean hospital stay was 17.5 days. Operative mortality was 3 percent, and morbidity was 62 percent. Using a grading scale for complications, 24 percent of patients had inconsequential complications, 16 percent had moderate complications, and 19 percent had severe complications. Complications were clearly related to extent of procedure. Factors that correlated best with morbidity were high blood loss and trisegmentectomy. The authors conclude that while hepatic resection can carry a high morbidity, much of this morbidity is minor and operative mortality is low. Recent improvements in anesthesia, improved resection technique, and a better understanding of hepatic anatomy have made possible correspondingly lower morbidity and mortality rates. Careful selection of patients can make hepatic resection a safe procedure.
Collapse
Affiliation(s)
- J T Vetto
- Department of Surgery, Lahey Clinic Medical Center, Burlington, Massachusetts 01805
| | | | | | | |
Collapse
|
34
|
Stephenson KR, Steinberg SM, Hughes KS, Vetto JT, Sugarbaker PH, Chang AE. Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastases. Ann Surg 1988; 208:679-87. [PMID: 3196088 PMCID: PMC1493828 DOI: 10.1097/00000658-198812000-00002] [Citation(s) in RCA: 187] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Data from fifty-five patients who had hepatic resections for colorectal liver metastases at the National Cancer Institute (NCI) were analyzed to determine the effect of perioperative blood transfusions on disease recurrence and overall survival. Besides blood transfusions, other factors included in the analysis were size, number, and distribution of metastases, margin status of resected metastases, length of disease-free interval, Duke's stage of the primary tumor, type of hepatic resection, and anesthesia time. Using the Cox proportional hazards model, the amount of blood transfused was found to be a significant prognostic factor. For each additional unit of blood transfused the risk of disease recurrence and death was increased by 5% (p = 0.0015) and 7% (p = 0.0013), respectively. The median disease-free survival for patients who received 3-5, 6-10, and greater than or equal to 11 transfused units was 26, 12.1, and 11.4 months, respectively. The median overall survival for patients who received 3-5, 6-10, and greater than or equal to 11 transfused units was greater than 44, 39.2, and 33.6 months, respectively. The number of resected nodules (1-2 vs. greater than or equal to 3), type of resection (anatomic lobectomy vs. wedge resection), and nodule size (less than or equal to 3.0 cm vs. greater than 3.0 cm) were additional factors that were further evaluated to determine the effect of blood transfusions. Analyses stratified for each of these factors revealed that patients who received greater than or equal to 11 units of blood had a significantly decreased disease-free and overall survival compared with patients who received 3-10 units of blood. It is concluded that the amount of perioperative blood transfused is an independent prognostic factor that adversely effects disease-free and overall survival.
Collapse
Affiliation(s)
- K R Stephenson
- Surgery Branch, National Cancer Institute, Bethesda, Maryland
| | | | | | | | | | | |
Collapse
|
35
|
Abstract
Focal hepatic lesions seen on roentgenologic evaluation of the liver in patients with cancer are usually assumed to be caused by parenchymal metastases. In this report, liver imaging tests showed six patients with filling defects caused by peritoneal carcinoma indenting the liver parenchyma. Extrahepatic tumor deposits were misdiagnosed in all but one of these cases. The roentgenographic characteristics that can assist in the differentiation of intrahepatic and extrahepatic metastases are a lens-shaped defect, a defect adjacent to the hemidiaphragm, and a halo around the liver suggesting peritoneal carcinomatosis. A high index of suspicion for extra-hepatic tumor masses causing intrahepatic filling defects may help prevent unnecessary exploratory surgery for treatment of hepatic metastases. Angiography may occasionally be helpful in distinguishing intrahepatic from extrahepatic disease.
Collapse
Affiliation(s)
- K S Hughes
- Winship Cancer Center, Emory University School of Medicine, Atlanta, GA 30322
| | | | | | | |
Collapse
|
36
|
Lefor AT, Hughes KS, Shiloni E, Steinberg SM, Vetto JT, Papa MZ, Sugarbaker PH, Chang AE. Intra-abdominal extrahepatic disease in patients with colorectal hepatic metastases. Dis Colon Rectum 1988; 31:100-3. [PMID: 3338339 DOI: 10.1007/bf02562637] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The resection of hepatic metastases in patients with extrahepatic disease is of no proven benefit. Preoperative identification of extrahepatic disease may prevent unnecessary laparotomy. Preoperative evaluation including physical examination, computed tomography of the abdomen, full lung tomography or chest-computed tomography, and radionuclide bone scanning identified extrahepatic metastases, most commonly in the lung, in 25 of 132 patients with purported isolated liver metastases. Of 107 patients with negative staging evaluations, intra-abdominal extrahepatic metastases were found in 26 percent (28 of 107) at laparotomy, most commonly in portal and celiac lymph nodes. The presence of extrahepatic disease correlated with greater than 25 percent hepatic replacement by tumor, presence of symptoms, and Dukes' C primary lesions; however, none was predictive. We were unable to develop a model to preoperatively predict the presence of intra-abdominal extrahepatic disease. The authors recommend a preoperative evaluation including physical examination, and computed tomographic scans of the abdomen and chest. A bone scan is required only in patients with symptoms referable to bone. Despite a negative preoperative evaluation, however, a considerable proportion of patients with colorectal hepatic metastases will have extrahepatic disease at the time of abdominal exploration.
Collapse
Affiliation(s)
- A T Lefor
- Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Hughes KS, Rosenstein RB, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG, Maclean BJ, Foster JH, Daly JM, Fitzherbert D. Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors. Dis Colon Rectum 1988; 31:1-4. [PMID: 3366020 PMCID: PMC3058509 DOI: 10.1007/bf02552560] [Citation(s) in RCA: 247] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
In this review of a collected series of patients undergoing hepatic resection for colorectal metastases, 100 patients were found to have survived greater than five years from the time of resection. Of these 100 long-term survivors, 71 remain disease-free through the last follow-up, 19 recurred prior to five years, and ten recurred after five years. Patient characteristics that may have contributed to survival were examined. Procedures performed included five trisegmentectomies, 32 lobectomies, 16 left lateral segmentectomies, and 45 wedge resections. The margin of resection was recorded in 27 patients, one of whom had a positive margin, nine of whom had a less than or equal to 1-cm margin, and 17 of whom had a greater than 1-cm margin. Eighty-one patients had a solitary metastasis to the liver, 11 patients had two metastases, one patient had three metastases, and four patients had four metastases. Thirty patients had Stage C primary carcinoma, 40 had Stage B primary carcinoma, and one had Stage A primary carcinoma. The disease-free interval from the time of colon resection to the time of liver resection was less than one year in 65 patients, and greater than one year in 34 patients. Three patients had bilobar metastases. Four of the patients had extrahepatic disease resected simultaneously with the liver resection. Though several contraindications to hepatic resection have been proposed in the past, five-year survival has been found in patients with extrahepatic disease resected simultaneously, patients with bilobar metastases, patients with multiple metastases, and patients with positive margins. Five-year disease-free survivors are also present in each of these subsets. It is concluded that five-year survival is possible in the presence of reported contraindications to resection, and therefore that the decision to resect the liver must be individualized.
Collapse
Affiliation(s)
- K S Hughes
- Division of Surgical Oncology, UCD Medical Center, Sacramento 95817
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Lefor AT, Hughes KS, Shiloni E, Steinberg SM, Vetto JT, Papa MZ, Sugarbaker PH, Chang AE. Staging of patients with suspected isolated colorectal liver metastases. Curr Surg 1987; 44:308-10. [PMID: 3665581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
39
|
Lee AH, Swaim SF, McGuire JA, Hughes KS. Effects of nonadherent dressing materials on the healing of open wounds in dogs. J Am Vet Med Assoc 1987; 190:416-22. [PMID: 3558079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Four types of nonadherent dressing materials (rayon/polyethylene dressing, cotton nonadherent film dressings, fine mesh gauze petrolatum dressings, and commercial petrolatum emulsion dressings) were applied on small full-thickness skin defects on the backs of 12 Beagles. At 7 days, the wounds treated with the petrolatum-containing dressings had more contraction than wounds dressed with cotton nonadherent film dressings and wounds dressed with rayon/polyethylene dressings. However, by days 14 and 21, there was little difference in the amount of contraction of any of the wounds. At 7, 14, and 21 days, the wounds dressed with petrolatum-containing dressings had less epithelialization than wounds dressed with cotton nonadherent film dressings and rayon/polyethylene dressings. The uniform open mesh of the commercial petrolatum emulsion dressings allowed the best absorption of exudate and bacteria into the secondary overlying bandage.
Collapse
|
40
|
Lee AH, Spano JS, Swaim SF, McGuire JA, Hughes KS. Evaluation of plasma and buffy coat ascorbic acid concentrations in dogs before and after a 24-hour fast. Am J Vet Res 1986; 47:2000-3. [PMID: 3767105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Samples of blood were taken from 15 female and 15 male research laboratory Beagles before and after they were fasted for 24 hours. The mean buffy coat ascorbic acid concentration was significantly higher in dogs after they were fasted than that before they were fasted. In contrast, the mean plasma ascorbic acid concentration was significantly lower in dogs after they were fasted than that before they were fasted. The mean buffy coat ascorbic acid concentrations in blood samples of both fasted and nonfasted female Beagles was significantly greater than those of male Beagles, whereas the mean plasma concentrations of both fasted and nonfasted female Beagles was significantly lower than those of male Beagles. It was observed that whenever there was a decrease in plasma ascorbic acid concentration, there was an increase in buffy coat ascorbic acid concentration, regardless of fasting stress or sex difference.
Collapse
|
41
|
Hughes KS, Simon R, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG, Maclean BJ, Foster JH, Daly JM, Fitzherbert D. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986; 100:278-84. [PMID: 3526605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The Registry of Hepatic Metastases has collected data on consecutive patients from 24 institutions who have undergone hepatic resection for colorectal carcinoma metastases. Patterns of recurrence were examined in a subgroup of 607 patients who had undergone curative resection of isolated hepatic metastases. Forty-three percent of these patient have had recurrences in the liver and 31% have had recurrences in the lung (either alone or in combination with other organs). A multivariate analysis showed that patients with positive pathologic margins or bilobar metastases were at an increased risk of having a recurrence in the liver (68% and 64%, respectively). We conclude that: hepatic resection effectively controls hepatic tumor in a substantial number of patients, adjuvant therapy after hepatic resection should be directed at both the lung and liver to significantly increase survival, and patients with positive pathologic margins or bilobar metastases are at an increased risk for hepatic recurrence.
Collapse
|
42
|
|
43
|
Hughes KS, Kowalsky TE, Copeland CE, Marrangoni AG, Turbiner EH. The effects of pressure and hepatocellular damage in biliary tract obstruction. Curr Surg 1984; 41:277-9. [PMID: 6541116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/05/2023]
|
44
|
Hughes KS, Marrangoni AG, Thompson DR, Turbiner E. Intrahepatic cholestasis as a cause of false-positive hepatobiliary scanning. Curr Surg 1984; 41:176-9. [PMID: 6540159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/05/2023]
|
45
|
Abstract
The records of all patients undergoing hepatobiliary imaging at our hospital from January 1980 to March 1983 were reviewed and 29 scans met the criteria for a pattern consistent with complete biliary tract obstruction. Biliary tract obstruction (due to choledocholithiasis, primary or secondary carcinoma involving the common bile duct, and pancreatitis) was documented in 24 of these patients. However, the remaining five patients had a patent common bile duct, and the etiologic factor was intrahepatic cholestasis secondary to sepsis in four and peritonitis in one. A classification of altered biliary dynamics in hepatobiliary imaging, which is based on the classification of jaundice, is proposed.
Collapse
|
46
|
Hughes KS, Villella ER. An improved technique for regional perfusion chemotherapy in the presence of a replaced right hepatic artery using a single implantable pump. Surgery 1984; 95:355-7. [PMID: 6701793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
A new technique is described for regional perfusion chemotherapy in the presence of a replaced right hepatic artery. By anastomosis of the replaced right hepatic artery end-to-side to the left hepatic artery, a single implantable pump can be used to perfuse both lobes of the liver. This technique has the advantage of facilitating postoperative follow-up and substantially reducing the cost of the procedure.
Collapse
|
47
|
Abstract
Hepatobiliary scans were obtained with Tc-99m-disofenin in 15 dogs. Of these, 5 served as controls, 5 were infused with E. coli endotoxin for 4 hours (endotoxic shock group), and 5 were bled to a mean pressure similar to that of the endotoxic shock group (hemorrhagic shock group). Scans of the controls and hemorrhagic shock group were identical. Scans of the endotoxic shock group were markedly abnormal, with a prolonged hepatic phase and little excretion of isotope into the biliary tract, a pattern characteristic of mechanical obstruction of the common bile duct. These results should alert the clinician to the potential danger of abnormal hepatobiliary scans in the septic patient.
Collapse
|